Anticuerpos anti-tiroglobulina en el seguimiento de pacientes con cáncer diferenciado de tiroides: ¿Marcadores de enfermedad residual o recidivante?

L, Iván Quevedo; J, Carmen Campino; Portales, José A. Rodríguez; U, Eugenio Arteaga; M, José Manuel López; M, Claudia Campusano; González, Gilberto; B, Carlos Fardella; M, Jenny Slater; Valdivia, Ligia; Poggi, Helena; C, Arnaldo Foradori; L, Soledad Velasco

doi:10.4067/s0034-98872002000200006

Cited by 11 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of TgAbs as a prognostic parameter in DTC remains controversial. While Rubello et al (18) and Adil et al (12) reported a higher frequency of relapse in association with persisting TgAbs after ablative therapy, the majority of authors (1,8,10,11) found no correlation, in agreement with our data. …”

Section: Prevalence and Development Of Tgabs In Dtc Patientssupporting

confidence: 81%

“…The TgAb kinetics in the course of patients with proven pre-existing lymphocytic thyroiditis did not differ significantly from that of patients without pre-existing AITD when evaluating only those cases in whom the initial TgAbs where higher than 40 U/ml. Quevedo et al (11) measured TgAb values in the course of the first 3 years in 26 DTC patients of whom 19 had coexisting lymphocytic thyroiditis and found significantly higher TgAb values in these patients as compared with those without thyroiditis. Chiovato et al (19) measured TgAbs using passive agglutination kits in the course of observation of 116 patients with DTC who initially had positive results for these antibodies, and of whom ten patients had coexisting Graves' disease and 34 patients Hashimoto's thyroiditis.…”

Section: Prevalence and Development Of Tgabs In Dtc Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy

et al. 2005

View full text Add to dashboard Cite

Objective and design: Cross-sectional studies have reported an increased prevalence of circulating thyroglobulin autoantibodies (TgAbs) in patients with differentiated thyroid carcinoma (DTC). With the advent of more sensitive assays, a longitudinal study monitoring the development of TgAb levels after ablative therapy was warranted. Methods: One hundred and twelve consecutive patients with follicular cell-derived thyroid cancer were followed for 3 years. All patients had been thyroidectomized and received, on average, two radioiodine therapies. Residual tissue was quantified scintigraphically by 131 I 24-h uptake. TgAb and thyroglobulin (Tg) serum levels were determined with a sensitive direct radioligand assay and an IRMA respectively. Results: The prevalence of TgAbs at the initial examination was 29% (median 130 U/ml). During follow-up, TgAb levels rose transiently in one-tenth of the patients, but the prevalence of demonstrable TgAbs decreased to , 10% after 3 years. The median serum half-life of TgAbs in treated DTC patients was 10 weeks. At initial examination (when all patients still had residual thyroid tissue and 17 had metastases), rising TgAb levels were correlated with the inability to detect Tg in 4, 30 and 73% of the patients, when initial TgAbs were , 6, 6 -50 or .50 U/ml respectively. While the Tg recovery test was valid for all patients, an in vitro dilution assay with TgAb serum reduced Tg values by up to 32%. Conclusions: The development and course of TgAbs in DTC patients cannot be predicted by initial or residual tumour volume, TgAb or Tg levels. The presence of TgAbs, even in low concentrations, may cause Tg underestimation despite valid recovery tests in DTC patients.European Journal of Endocrinology 153 49-55

show abstract